1. Metabolic Enzyme/Protease Anti-infection
  2. HIV Integrase HIV
  3. Raltegravir potassium

Raltegravir potassium  (Synonyms: MK 0518 potassium)

Cat. No.: HY-10353A Purity: 99.51%
Data Sheet SDS COA Handling Instructions

Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.

For research use only. We do not sell to patients.

Raltegravir potassium Chemical Structure

Raltegravir potassium Chemical Structure

CAS No. : 871038-72-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 30 In-stock
Solution
10 mM * 1 mL in DMSO USD 32 In-stock
Solid
5 mg USD 30 In-stock
10 mg USD 45 In-stock
50 mg USD 130 In-stock
100 mg USD 220 In-stock
200 mg   Get quote  
500 mg   Get quote  

Get it December 30 by noon. Order within 1 hrs 16 mins.

* Please select Quantity before adding items.

Customer Review

Based on 22 publication(s) in Google Scholar

Other Forms of Raltegravir potassium:

Top Publications Citing Use of Products

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: J Neuroimmune Pharmacol. 2017 Dec;12(4):682-692.  [Abstract]

    TDF/FTC/RAL combined medication induces mouse NPC apoptosis in vitro. Mouse NPCs are treated with either DMSO or TDF/FTC/RAL for 8 h. Cleaved Caspase-3 levels are determined by Western blotting.

    Raltegravir potassium purchased from MedChemExpress. Usage Cited in: J Virol. 2017 Jan 18;91(3). pii: e02152-16.  [Abstract]

    Inhibitory effects of Raltegravir on pUL89-C activity analyzed by agarose gel assay. Linearized pUC18 in the absence (Lane 1) or presence (Lane 2) of pUL89-C. Lanes 3–10: A range of concentrations of Raltegravir with pUL89-C. Numbers above bands correspond to the fold change compared with the control.

    View All HIV Isoform Specific Products:

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.

    IC50 & Target

    HIV-1

     

    HIV-2

     

    Cellular Effect
    Cell Line Type Value Description References
    HEK-293T IC50
    2 nM
    Compound: 1, RAL, Raltegravir
    Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days
    Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days
    [PMID: 23845180]
    HEK-293T IC50
    7.1 nM
    Compound: 1, RAL, Raltegravir
    Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days in presence of human serum albumin
    Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days in presence of human serum albumin
    [PMID: 23845180]
    MT2 EC50
    0.26 nM
    Compound: RAL, Raltegravir, MK-0518
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect measured after 2 to 3 days by PCR
    [PMID: 21115794]
    MT2 EC50
    0.26 nM
    Compound: RAL, Raltegravir, MK-0518
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 14 passages measured after 2 to 3 days by PCR
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A mutant gene infected in human MT2 cells assessed as inhibition of virus induced cytopathic effect selected after 14 passages measured after 2 to 3 days by PCR
    [PMID: 21115794]
    MT2 EC50
    0.26 nM
    Compound: RAL, Raltegravir, MK-0518
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A,Q148K,N155H/I204T mutant infected in human MT2 cells assessed as inhibition of virus-induced effect selected on day 28 after 8 passages by PCR
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A,Q148K,N155H/I204T mutant infected in human MT2 cells assessed as inhibition of virus-induced effect selected on day 28 after 8 passages by PCR
    [PMID: 21115794]
    MT2 EC50
    1.3 nM
    Compound: RAL, Raltegravir, MK-0518
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase G59E, T124A,Q148K, Q148R,N155H, N155H/I204T mutant infected in human MT2 cells assessed as inhibition of virus-induced effect selected on day 42 after 12 passages by PCR
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase G59E, T124A,Q148K, Q148R,N155H, N155H/I204T mutant infected in human MT2 cells assessed as inhibition of virus-induced effect selected on day 42 after 12 passages by PCR
    [PMID: 21115794]
    MT2 EC50
    32 nM
    Compound: RAL, Raltegravir, MK-0518
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A,Q148K,Q148R,E138K/Q148K,E138K/Q148R,G140S/Q148R,V151I/N155H,N155H/I204T,N17S/Q148K/G163R,T124A/V151I/N155H,E138K/Q148K/G163R,G140C/Q148K/G163R,E92Q/E138K/Q148K/M154I mu
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A,Q148K,Q148R,E138K/Q148K,E138K/Q148R,G140S/Q148R,V151I/N155H,N155H/I204T,N17S/Q148K/G163R,T124A/V151I/N155H,E138K/Q148K/G163R,G140C/Q148K/G163R,E92Q/E138K/Q148K/M154I mu
    [PMID: 21115794]
    MT2 EC50
    6.4 nM
    Compound: RAL, Raltegravir, MK-0518
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A,Q148K,Q148R,N17S/Q148K,E92Q/M154I,G140C/Q148K,G140S/Q148R,Q148K/G163R,V151I/N155H, N155H/I204T,T124A/V151I/N155H,G140C/Q148K/G163R mutant infected in human MT2 cells as
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A,Q148K,Q148R,N17S/Q148K,E92Q/M154I,G140C/Q148K,G140S/Q148R,Q148K/G163R,V151I/N155H, N155H/I204T,T124A/V151I/N155H,G140C/Q148K/G163R mutant infected in human MT2 cells as
    [PMID: 21115794]
    MT2 EC50
    6.4 nM
    Compound: RAL, Raltegravir, MK-0518
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A, Q148K,Q148R, N155H, E92Q/M154I,Q148K/G163R, N155H/I204T mutant infected in human MT2 cells assessed as inhibition of virus-induced effect selected on day 56 after 16 p
    Antiviral activity against Human immunodeficiency virus 1 3B harboring integrase T124A, Q148K,Q148R, N155H, E92Q/M154I,Q148K/G163R, N155H/I204T mutant infected in human MT2 cells assessed as inhibition of virus-induced effect selected on day 56 after 16 p
    [PMID: 21115794]
    MT4 CC50
    > 51.8 μM
    Compound: Raltegravir-K
    Cytotoxic activity against mock-infected human MT4 cellls assessed as reduction in cell viability by MTT assay
    Cytotoxic activity against mock-infected human MT4 cellls assessed as reduction in cell viability by MTT assay
    [PMID: 28951095]
    In Vitro

    PFV IN carrying the S217H substitution is 10-fold less susceptible to Raltegravir with IC50 of 900 nM. PFV IN displays 10% of WT activity and is inhibited by Raltegravir with an IC50 of 200 nM, indicating a appr twofold decrease in susceptibility to the IN strand transfer inhibitor (INSTI) compared with WT IN. S217Q PFV IN is as sensitive to Raltegravir as the WT enzyme[1]. Raltegravir is metabolized by glucuronidation, not hepatically. Raltegravir has potent in vitro activity against HIV-1, with a 95% inhibitory concentration of 31±20 nM, in human T lymphoid cell cultures. Raltegravir is also active against HIV-2 when Raltegravir is tested in CEMx174 cells, with an IC95 of 6 nM. Raltegravir metabolism occurs primarily through glucuronidation. Drugs that are strong inducers of the glucuronidation enzyme, UGT1A1, significantly reduce Raltegravir concentrations and should not be used. Raltegravir exhibits weak inhibitory effects on hepatic cytochrome P450 activity. Raltegravir does not induce CYP3A4 RNA expression or CYP3A4-dependent testosterone 6-β-hydroxylase activity[2]. Raltegravir cellular permeativity is reduced in the presence of magnesium and calcium[3]. Raltegravir and related HIV-1 integrase (IN) strand transfer inhibitors (INSTIs efficiently block viral replication[4]. In acutely infected human lymphoid CD4+ T-cell lines MT-4 and CEMx174, SIVmac251 replication is efficiently inhibited by Raltegravir, which shows an EC90 in the low nanomolar range[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    In Vivo

    Raltegravir induces viro-immunological improvement of nonhuman primates with progressing SIVmac251 infection. One non-human primate shows an undetectable viral load following Raltegravir monotherapy[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial
    Molecular Weight

    482.51

    Formula

    C20H20FKN6O5

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(C(N=C(C(NC(C1=NN=C(C)O1)=O)(C)C)N2C)=C(O[K])C2=O)NCC3=CC=C(F)C=C3

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    Solvent & Solubility
    In Vitro: 

    H2O : 25 mg/mL (51.81 mM; Need ultrasonic)

    DMSO : 20.83 mg/mL (43.17 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.0725 mL 10.3625 mL 20.7250 mL
    5 mM 0.4145 mL 2.0725 mL 4.1450 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 25 mg/mL (51.81 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Purity & Documentation

    Purity: 99.96%

    References
    Cell Assay
    [5]

    Human MT-4 cells are infected for 2 hours with the SIVmac251, HIV-1 (IIIB) and HIV-2 (CDC 77618) stocks at a multiplicity of infection of, approximately, 0.1. Cells are then washed three times in phosphate buffered saline, and suspended at 5 × 105/mL in fresh culture medium (to primary cells 50 units/mL of IL-2 are added) in 96-well plates, in the presence or absence of a range of triplicate raltegravir concentrations (0.0001 μM-1 μM). Untreated infected and mock-infected controls are prepared too, in order to allow comparison of the data derived from the different treatments. Viral cytopathogeniciy in MT-4 cells is quantitated by the methyl tetrazolium (MTT) method (MT-4/MTT assay) when extensive cell death in control virus-infected cell cultures is detectable microscopically as lack of capacity to re-cluster. The capability of MT-4 cells to form clusters after infection. Briefly, clusters are disrupted by pipetting; and, after 2 hours of incubation at 37°C, the formation of new clusters is assessed by light microscopy (100× magnification). Cell culture supernatants are collected for HIV-1 p24 and HIV-2/SIVmac251 p27 core antigen measurement by ELISA. In CEMx174-infected cell cultures, which show a propensity to form syncytia induced by the virus envelope glycoproteins, syncytia are counted, in blinded fashion, by light microscopy for each well at 5 days following infection.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 2.0725 mL 10.3625 mL 20.7250 mL 51.8124 mL
    5 mM 0.4145 mL 2.0725 mL 4.1450 mL 10.3625 mL
    10 mM 0.2072 mL 1.0362 mL 2.0725 mL 5.1812 mL
    15 mM 0.1382 mL 0.6908 mL 1.3817 mL 3.4542 mL
    20 mM 0.1036 mL 0.5181 mL 1.0362 mL 2.5906 mL
    25 mM 0.0829 mL 0.4145 mL 0.8290 mL 2.0725 mL
    30 mM 0.0691 mL 0.3454 mL 0.6908 mL 1.7271 mL
    40 mM 0.0518 mL 0.2591 mL 0.5181 mL 1.2953 mL
    H2O 50 mM 0.0414 mL 0.2072 mL 0.4145 mL 1.0362 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Raltegravir potassium
    Cat. No.:
    HY-10353A
    Quantity:
    MCE Japan Authorized Agent: